• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Novo Nordisk’s ziltivekimab hits primary endpoint in CKD trial pharmatimes
    May 18, 2021
    Novo Nordisk’s investigational interleukin-6 (IL-6) inhibitor ziltivekimab met the primary endpoint in a Phase II trial in people with advanced chronic kidney disease (CKD) and elevated high-sensitivity C-reactive protein (hsCRP), representing high ...
  • Novo snaps up cardio-renal group Corvidia pharmatimes
    June 16, 2020
    Novo Nordisk has signed a deal to acquire Corvidia Therapeutics, a privately held, clinical stage company with a focus on the research and development of transformative therapies for cardio-renal diseases.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service